期刊文献+

肿瘤M2型丙酮酸激酶在结肠癌诊断中的意义 被引量:2

The value of tumor M2 pyruvate kinase in diagnosis of colon cancer
原文传递
导出
摘要 目的评估肿瘤M2型丙酮酸激酶(M2-PK)在结肠癌的诊断、筛查以及肿瘤分期中的意义。方法用ELISA检测结肠癌33例,结肠腺瘤27例以及正常对照30例的血浆及粪便中肿瘤M2-PK的数值,同时用化学发光法(CL)检测结肠癌患者癌胚抗原(CEA)的水平,并进行相关分析。结果结肠癌组血浆及粪便肿瘤M2-PK水平显著高于结肠腺瘤组及正常对照组(P<0.05),但结肠腺瘤组与正常对照组差异无统计学意义(P>0.05)。结肠癌Dukes C、D期患者的血浆及粪便中肿瘤M2-PK水平明显高于A、B期患者(P<0.05),有淋巴转移者明显高于无淋巴转移者(P<0.05)。血浆和粪便肿瘤M2-PK对结肠癌诊断的敏感性分别为84.8%和78.8%,高于CEA的51.5%。结论肿瘤M2-PK对结肠癌的诊断具有临床价值,敏感性高于CEA,并且与肿瘤的分期密切相关,可用于结肠癌的筛查及诊断。 Objective To evaluate the value of tumor M2 pyruvate kinase(M2-PK) in diagnosing,screening and staging colon cancer.Methods The levels of tumor M2-PK in plasma and fecal were determined by ELISA in 33 patients with colon cancer(group A),27 patients with colon polyp(group B) and 30 healthy controls(group C).Dukes staging of the tumors was performed as well.Carcinoembryonic antigen(CEA) was simultaneously determined by chemiluminescence in group A.Results The level of tumor M2-PK was significantly higher in group A than that in groups of B and C(P0.05),which was not significantly different between groups of B and C(P0.05).The levels of tumor M2-PK were higher in cases with Dukes staging C and D than those with Dukes staging A and B(P0.05).The level of tumor M2-PK was higher in patients with lymph node metastasis than that without(P0.05).The sensitivity of tumor M2-PK in plasma and fecal was 84.8% and 78.8%,respectively,which was significantly higher than 51.5% for that of CEA.Conclusion Tumor M2-PK in fecal and plasma has clinical value in diagnosis of colon cancer.The sensitivity of tumor M2-PK for colon cancer is higher than that of CEA.Tumor M2-PK is correlated to the stage of colon cancer and may be helpful for screening and diagnosing colon cancer.
出处 《江苏医药》 CAS CSCD 北大核心 2011年第5期523-525,共3页 Jiangsu Medical Journal
基金 南京医科大学科技发展基金面上项目(08NMUM094)
关键词 肿瘤M2型丙酮酸激酶 结肠癌 癌胚抗原 Tumor M2 pyruvate kinase Colon cancer Carcinoembryonic antigen
  • 相关文献

参考文献10

  • 1Haug U, Hundt S, Brenner H, et al. Sensitivity and specificity of fecal turnour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study[J]. Br J Cancer, 2008,99 (1):133-135.
  • 2Onouchi S, Matsushita H, New method for colorectal cancer diagnosis based on SSCP analysis of DNA from exfoliated colonocytes in naturally evacuated feces[J]. Anticancer Res, 2008,28(1) : 145-150.
  • 3Mazurek S,Boschek CBrHugo F, et al. Pyruvate kinase type M2 and its role in tumor growth and spreading[J]. Semin Cancer Biol, 2005,15 (4) : 300-308.
  • 4Ivanova A, Iarumov N, Toshev s, et ak Pilot study on M2-PK-a new non-invasive parameter for early diagnosis of coloreetal earcinoma[J]. Khirurgiia(Sofiia), 2007,10(6) : 5-7.
  • 5叶维洁,金冶宁.结直肠恶性肿瘤的新标志物—肿瘤型丙酮酸激酶[J].现代肿瘤医学,2009,17(10):2018-2020. 被引量:5
  • 6Carolin Tonus,Gero Neupert, Markus Sellinge, et al. Colorec- tal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK[J]. World J Gastroenterol, 2007,13 (19) : 2768- 2769.
  • 7Schneider J, Bitterlich N, Schulze G, et al. Improved seneitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic- based tumor marker profiles including the tumor M2-PK[J]. Anticancer Res,2005,25 (3) : 1507-1515.
  • 8卢仁泉,郭林,许晓峰.胃肠道恶性肿瘤患者血浆肿瘤型M2-丙酮酸激酶的测定及其临床价值[J].检验医学,2008,23(4):370-373. 被引量:13
  • 9Shastri YM, Naumann M, Oremek GM, et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia [J]. Int J Cancer, 2006,119(11) : 2651-2656.
  • 10Koss K, Maxton D, Jankowski JA, et al. Faecal dimerie M2 pyruvate kinase in colorectal cancer and polyps correlates with turnout staging and surgical intervention[J]. Colorectal Dis, 2008,10(3) : 244-248.

二级参考文献28

  • 1厉明,梅同华.肺癌新标志——肿瘤M2型丙酮酸激酶[J].国际检验医学杂志,2006,27(5):446-447. 被引量:9
  • 2Prakin DM. Global cancer statistics in year 2000 [ J ]. Lancet Oncol,2001,2:533 - 543.
  • 3Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2 - pyruvate kinase : a promising tumor marker in the diagnosis of gastro - intestinal cancer[ J ]. Anticancer Res,2000 ,20 :4965 - 4968.
  • 4Lftner D,Mesterharm J,Akrivakis C ,et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer[ J]. Anticancer Res, 2000,20(6D) :5077 - 5082.
  • 5Oremek GM, Gerstmeier F, Sauer - Eppel H, et al. Pre - analytical problems in the measurement of tumor type pyruvate kinase (tumor M2 - PK) [ J]. Anticancer Res ,2003,23 (2A) : 1127 - 1130.
  • 6Ewald N, Schaller M, Bayer M, et al. Fecal pyruvate kinase - M2 ( tumor M2 - PK) measurement:a new screening concept for colorectal cancer[ J ]. Anticancer Res,2007,27 (4A) : 1949 - 1952.
  • 7Shastri YM, Naumann M, Oremek GM, et al. Prospective multicenter evaluation of fecal tumor pyravate kinase type M2 ( M2 - PK) as a screening biomarker for colorectal neoplasia[ J]. lnt J Cancer,2006,119(11) :2651 -2656.
  • 8Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention[ J ]. Colorectal Dis ,2008,10 (3) :244 - 248.
  • 9Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase : a new, sensitive screening tool for colorectal cancer [J]. Br J Cancer,2004,91 (5) :980 -984.
  • 10Schneider J, Schulze G. Comparison of tumor M2 pyruvate kinase ( tumor M2 - PK ) , carcinoembryonic antigen ( CEA ) , carbohydrate antigens CA19- 9 and CA72 -4 in the diagnosis of gastrointestinal cancer [ J ]. Anticaneer Res, 2003,23 ( 6D ) : 5089 -5093.

共引文献16

同被引文献18

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部